Bujan L, Bachaud J M, Chevreau C, Pontonnier F, Mansat A, Mieusset R
Centre de Stérilité Masculine, CHU La Grave, Toulouse.
Contracept Fertil Sex. 1996 Jul-Aug;24(7-8):596-602.
The deleterious effects of chimio or radio-therapy on spermatogenesis of men treated for testicular cancer are well known. Retroperitoneal lymphadenectomy is a risk for ejaculation process. Semen cryopreservation seems to be obligatory before any deleterious treatment. Prophylactic measures do exist such as lead protection during x-rays therapy, drugs with less toxicity but similar efficiency, selective lymphadenectomy. Moreover, positive results were reported form realised in animals to protect spermatogenesis. In men treated for testicular cancer, 4 protective studies were reported using either GnRH analogs (3 studies) or medroxyprogesterone (one study). No protective effects were obtained in these trials, and the reasons for such failure are discussed. Finally, new potential possibilities of spermatogenesis protection are suggested supported by the results of animal experiments or the occurrence of new drugs such as use of steroids, GnRH antagonist or testicular hypothermia.
化疗或放疗对接受睾丸癌治疗的男性精子发生的有害影响是众所周知的。腹膜后淋巴结清扫术对射精过程有风险。在进行任何有害治疗之前,精液冷冻保存似乎是必要的。确实存在一些预防措施,例如在x射线治疗期间进行铅防护、使用毒性较小但疗效相似的药物、选择性淋巴结清扫术。此外,在动物实验中实现了保护精子发生的阳性结果。在接受睾丸癌治疗的男性中,有4项保护研究报告,其中3项使用促性腺激素释放激素类似物,1项使用甲羟孕酮。在这些试验中未获得保护作用,并对这种失败的原因进行了讨论。最后,动物实验结果或新药物(如类固醇、促性腺激素释放激素拮抗剂或睾丸低温)的出现为精子发生保护提供了新的潜在可能性。